The article describes improvements in the FDA's drug safety oversight that go beyond the mere publication of daily adverse event data. The FDA has expanded its statistical analysis capabilities and introduced new scientific tools to better detect potential safety problems in post-marketing drugs. These changes also include the national electronic Sentinel system, which enables faster and more efficient monitoring of drug safety using access to health data. The FDA now oversees the safety of both innovative and generic drugs with the same rigor as in preclinical evaluation. The transparency and speed of decisions on solving security issues and communication with the public are also improved. These measures aim to increase the protection of patients against adverse effects and prevent errors in the use of medicines. The entire process of supervision thus becomes more complex and active during the entire life cycle of the drug[3].